The presentation on the 24th and the conference call on the 25th would have to provide unprecedented and strong evidence that the ReACT trial is demonstrating that Rindo is helping Avastin refractory GBM patients survive against all odds in order for that to happen. It could happen.
already in the abstract data from May there is one confirmed complete responder and another borderline complete. 1 in 10 complete responders would be exceptional data, more would be ridiculously great. Look at the recent Merck data on their checkpoint (PD-1) inhibitor that showed 1 in 10 complete responders and this was hailed as hugely positive for the drug and class of new compounds in melanoma. These patients have no other options and Avastin isn't working at all- one in 10 complete responders would be clear and present victory for Rindo, Celldex, patients and stakeholders.